The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO
Open accessAbstract
Purpose: To develop a simple scoring system for the likelihood of identifying a BRCA1 or BRCA2 mutation. Methods: DNA samples from affected subjects from 422 non-Jewish families with a history of breast and/or ovarian cancer were screened for BRCA1 mutations and a subset of 318 was screened for BRCA2 by whole gene screening techniques. Using a combination of results from screening and the family history of mutation negative and positive kindreds, a simple scoring system (Manchester scoring system) was devised to predict pathogenic mutations and particularly to discriminate at the 10% likelihood level. A second separate dataset of 192 samples was subsequently used to test the model’s predictive value. This was further validated on a third set of 258 samples and compared against existing models. Results: The scoring system includes a cut-off at 10 points for each gene. This equates to >10% probability of a pathogenic mutation in BRCA1 and BRCA2 individually. The Manchester scoring system had the best trade-off between sensitivity and specificity at 10% prediction for the presence of mutations as shown by its highest C-statistic and was far superior to BRCAPRO. Conclusion: The scoring system is useful in identifying mutations particularly in BRCA2. The algorithm may need modifying to include pathological data when calculating whether to screen for BRCA1 mutations. It is considerably less time-consuming for clinicians than using computer models and if implemented routinely in clinical practice will aid in selecting families most suitable for DNA sampling for diagnostic testing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families
Ford, D., Easton, D. F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., Bishop, D. T., Weber, B., Lenoir, G., Chang-Claude, J., et al. (1998) · The American Journal of Human Genetics · doi:10.1086/301749 · Cited by 3,037
Cancer Risks in BRCA2 Mutation Carriers
Breast Cancer Linkage Consortium, T. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.15.1310 · Cited by 1,527
Pochon, S. (2005) · American Journal of Cancer · doi:10.2165/00024669-200504040-00008 · Cited by 1,424
Prevalence of BRCA1 and BRCA2 Gene Mutations in Patients With Early-Onset Breast Cancer
Peto, J., Collins, N., Barfoot, R., Seal, S., Warren, W., Rahman, N., Easton, D. F., Evans, C., Deacon, J., & Stratton, M. R. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.11.943 · Cited by 873
Self-citationLakhani, S. R., van de Vijver, M. J., Jacquemier, J., Anderson, T. J., Osin, P. P., McGuffog, L., & Easton, D. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.023 · Cited by 823
Determining Carrier Probabilities for Breast Cancer–Susceptibility Genes BRCA1 and BRCA2
Parmigiani, G., Berry, D. A., & Aguilar, O. (1998) · The American Journal of Human Genetics · doi:10.1086/301670 · Cited by 753
BRCA1 Mutations in Women Attending Clinics That Evaluate the Risk of Breast Cancer
Couch, F. J., DeShano, M. L., Blackwood, M. A., Calzone, K., Stopfer, J., Campeau, L., Ganguly, A., Rebbeck, T., Weber, B. L., Jablon, L., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705153362002 · Cited by 685
Ganguly, A., Rock, M. J., & Prockop, D. J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.21.10325 · Cited by 674
Frank, T. S., Deffenbaugh, A. M., Reid, J. E., Hulick, M., Ward, B. E., Lingenfelter, B., Gumpper, K. L., Scholl, T., Tavtigian, S. V., Pruss, D. R., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.6.1480 · Cited by 558
Berry, D. A., Iversen, E. S., Gudbjartsson, D. F., Hiller, E. H., Garber, J. E., Peshkin, B. N., Lerman, C., Watson, P., Lynch, H. T., Hilsenbeck, S. G., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.05.121 · Cited by 505
Research works printed but not linked: 13
- 1997, Am J Hum Genet, 60, 1013
- 1996, Cancer Res, 56, 3663
- 2000, Am J Hum Genet, 77, 207
- 10.1136/jmg.37.12.e42 · doi:10.1136/jmg.37.12.e42
- 10.1200/JCO.20.6.1480 · doi:10.1200/jco.20.6.1480 · Paper page
- 10.1136/jmg.40.7.503 · doi:10.1136/jmg.40.7.503
- Peelen T. Genetics of hereditary breast and ovarian cancer in the Netherlands. Leiden, The Netherlands: PhD thesis, Leiden University, 2001:115–28.
- 10.1054/bjoc.2000.1626 · doi:10.1054/bjoc.2000.1626
- 10.1002/ijc.10527 · doi:10.1002/ijc.10527
- 2002, Familial Cancer, 3, 131
- 10.1136/jmg.35.1.10 · DOI
- 1996, J Clin Oncol, 14, 1730, 10.1200/JCO.1996.14.5.1730 · DOI · Paper page
- 10.1016/S0046-8177(00)80014-3 · DOI
Cited by
The BOADICEA model of genetic susceptibility to breast and ovarian cancer
Antoniou, A. C., Pharoah, P. P. D., Smith, P., & Easton, D. F. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602175 · Cited by 467
US Preventive Services Task Force, Owens, D. K., Davidson, K. W., Krist, A. H., Barry, M. J., Cabana, M., Caughey, A. B., Doubeni, C. A., Epling, J. W., Kubik, M., et al. (2019) · JAMA · doi:10.1001/jama.2019.10987 · Cited by 467
Assessing Women at High Risk of Breast Cancer: A Review of Risk Assessment Models
Amir, E., Freedman, O. C., Seruga, B., & Evans, D. G. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq088 · Cited by 464
Self-citationMoyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2014) · Annals of Internal Medicine · doi:10.7326/m13-2747 · Cited by 409
U.S. Preventive Services Task Force* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-5-200509060-00011 · Cited by 405
Nelson, H. D., Huffman, L. H., Fu, R., & Harris, E. L. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-5-200509060-00012 · Cited by 346
Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2
Petrucelli, N., Daly, M. B., & Feldman, G. L. (2010) · Genetics in Medicine · doi:10.1097/gim.0b013e3181d38f2f · Cited by 339
Nelson, H. D., Pappas, M., Zakher, B., Mitchell, J. P., Okinaka-Hu, L., & Fu, R. (2014) · Annals of Internal Medicine · doi:10.7326/m13-1684 · Cited by 319
Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification
Bunyan, D. J., Eccles, D. M., Sillibourne, J., Wilkins, E., Thomas, N. S., Shea-Simonds, J., Duncan, P. J., Curtis, C. E., Robinson, D. O., Harvey, J. F., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602121 · Cited by 264
Self-citationManagement of an Inherited Predisposition to Breast Cancer
Robson, M., & Offit, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmcp071286 · Cited by 252
Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer
George, A., Kaye, S., & Banerjee, S. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.191 · Cited by 158
Evans, D. G. R., van Veen, E. M., Byers, H. J., Wallace, A. J., Ellingford, J. M., Beaman, G., Santoyo-Lopez, J., Aitman, T. J., Eccles, D. M., Lalloo, F. I., et al. (2018) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2018.07.002 · Cited by 95
Self-citationEvans, D. G. R., Moran, A., Hartley, R., Dawson, J., Bulman, B., Knox, F., Howell, A., & Lalloo, F. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605606 · Cited by 52
Self-citationvan den Broek, A. J., de Ruiter, K., van 't Veer, L. J., Tollenaar, R. A. E. M., van Leeuwen, F. E., Verhoef, S., & Schmidt, M. K. (2015) · European Journal of Human Genetics · doi:10.1038/ejhg.2014.161 · Cited by 18
Metadata
- Authors
- Evans, D. G. R., Eccles, D. M., Rahman, N., Young, K., Bulman, M., Amir, E., Shenton, A., Howell, A., & Lalloo, F.
- Venue
- Journal of Medical Genetics
- Publisher
- BMJ
- Published
- 2004-06
- Volume
- 41
- Issue
- 6
- Pages
- 474-480
- ISSN
- 0022-2593 (ISSN-L)
- 1468-6244
- OpenAlex
- W2126170418
- Cited by
- 265
- References
- 32
- FWCI
- 6.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.